WO1995021626A1 - Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques - Google Patents

Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques Download PDF

Info

Publication number
WO1995021626A1
WO1995021626A1 PCT/US1995/001829 US9501829W WO9521626A1 WO 1995021626 A1 WO1995021626 A1 WO 1995021626A1 US 9501829 W US9501829 W US 9501829W WO 9521626 A1 WO9521626 A1 WO 9521626A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
residue
seq
amino acid
amino acids
Prior art date
Application number
PCT/US1995/001829
Other languages
English (en)
Inventor
Kenneth Kaushansky
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington filed Critical University Of Washington
Priority to EP95910252A priority Critical patent/EP0723456A1/fr
Priority to NZ281482A priority patent/NZ281482A/xx
Priority to CA002169173A priority patent/CA2169173C/fr
Priority to AU18435/95A priority patent/AU1843595A/en
Publication of WO1995021626A1 publication Critical patent/WO1995021626A1/fr
Priority to FI960930A priority patent/FI960930A0/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Definitions

  • Hematopoiesis is the process by which blood cells develop and differentiate from pluripotent stem cells in the bone marrow. This process involves a complex interplay of polypeptide growth factors (cytokines) acting via membrane-bound receptors on the target cells. Cytokine action results in cellular proliferation and differentiation, with response to a particular cytokine often being lineage-specific and/or stage-specific. Development of a single cell type, such as a platelet or erythrocyte, from a stem cell may require the coordinated action of a plurality of cytokines acting in the proper sequence.
  • cytokines polypeptide growth factors
  • the known cytokines include the interleukins , such as IL-1, IL-2, IL-3, IL-6, IL-8 , etc.; and the colony stimulating factors, such as G-CSF, M-CSF, GM-CSF, erythropoietin (EPO) , etc.
  • the interleukins act as mediators of immune and inflammatory responses.
  • the colony stimulating factors stimulate the proliferation of marrow-derived cells, activate mature leukocytes, and otherwise form an integral part of the host's response to inflammatory, infectious, and im unologic challenges.
  • Various cytokines have been developed as therapeutic agents. Several of the colony stimulating factors have been used in conjunction with cancer chemotherapy to speed the recovery of patients' immune systems.
  • Interleukin-2, ⁇ -interferon and 7-interferon are used in the treatment of certain cancers.
  • EPO which stimulates the development of erythrocytes, is used in the treatment of anemia arising from renal failure.
  • Factors responsible for stimulation of megakaryocytopoiesis and thrombocytopoiesis resisted definitive characterization, due in part to lack of a good source, a lack of good assays, and a lack of knowledge as to the site(s) of production until recently, despite three decades of work to isolate and characterize them.
  • the megakaryocytopoietic factor referred to in the literature as "thrombopoietin" (recently reviewed by McDonald, Exp. Hematol.
  • Mild bleeding disorders (MBDs) associated with platelet dysfunctions are relatively common (Bachmann, Seminars in He atoloqy 17: 292-305, 1980) , as are a number of congenital disorders of platelet function, including Bernard-Soulier syndrome (deficiency in platelet GPIb) , Glanzmann's thrombasthenia (deficiency of GPIIb and GPIIIa) , congenital afibrinogene ia (diminished or absent levels of fibrinogen in plasma and platelets) , and gray platelet syndrome (absence of tt-granules) .
  • Anemias are deficiencies in the production of red blood cells (erythrocytes) and result in a reduction in the level of oxygen transported by blood to the tissues of the body.
  • Hypoxia may be caused by loss of large amounts of blood through hemorrhage, destruction of red blood cells from exposure to autoantibodies, radiation or chemicals, reduction in oxygen intake due to high altitudes or prolonged unconsciousness.
  • hypoxia is present in tissue, EPO production is stimulated and increases red blood cell production.
  • EPO promotes the conversion of primitive precursor cells in the bone marrow into pro-erythrocytes which subsequently mature, synthesize hemoglobin and are released into the circulation as red blood cells.
  • the level of EPO in circulation is decreased.
  • Severe reductions in both megakaryocyte and erythrocyte levels can be associated with the treatment of various cancers with chemotherapy and radiation and diseases such as AIDS, aplastic anemia and myelodysplasias.
  • Levels of megakaryocytes and/or erythrocytes that become too low, for example, platelet counts below 25,000 to 50,000 and hematocrits of less than 25 are likely to produce considerable morbidity and in certain circumstances these levels are life-threatening.
  • specific treatments include platelet transfusions for thrombocytopenia (low megakaryocyte levels) and stimulation of erythropoiesis using EPO or transfusion of red blood cells for anemia.
  • TPO in amount sufficient to increase reticulocyte counts and erythroid colony formation.
  • the present invention provides that the TPO is human TPO.
  • the TPO comprises of a sequence of amino acids selected from group consisting of: the sequence of amino acids shown in SEQ ID NO:2 from amino acid residue 1 to residue 172; the sequence of amino acids shown in SEQ ID NO:2 from amino acid residue 1 to residue 173; the sequence of amino acids shown in SEQ ID NO:2 from amino acid residue 1 to residue 175; the sequence of amino acids shown in SEQ ID NO:2 from amino acid residue 1 to amino acid residue 353; the sequence of amino acids shown in SEQ ID NO:2 from amino acid residue 22 to residue 353; the sequence of amino acids shown in SEQ ID NO:2 from amino acid residue 22 to residue 172; the sequence of amino acids shown in SEQ ID NO:2 from amino acid residue 22 to residue 173; the sequence of amino acids shown in SEQ ID NO:2 from amino acid residue 22 to residue 175; the sequence of amino acids shown in SEQ ID NO:2 from amino acid residue 28 to residue 172; the sequence of amino acids shown in
  • the invention provides methods where a mammal is administered TPO of 1 x 10 5 to 100 x 10 5 units TPO/kg/day, preferably 5 x 10 5 to 50 x 10 5 units TPO/kg/day.
  • the invention provides methods where a mammal is administered TPO of 1 x 10 5 to 100 x 10 5 units TPO/kg/day, preferably 5 x 10 5 to 50 x 10 5 units TPO/kg/day and EPO of 1 to 150 units EPO/kg/day.
  • Figure 1 illustrates that following the addition of TPO and EPO to cultured bone marrow cells, erythroid colony formation is enhanced relative to addition of EPO alone.
  • Figure 2 illustrates that following the addition of TPO to animals made pancytopenic with prior irradiation and chemotherapy, the decline in red blood cell count is not as severe, and returns to normal sooner in animals given TPO.
  • Allelic variant An alternative form of a gene that arises through mutation, or an altered polypeptide encoded by the mutated gene. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence.
  • cDNA Complementary DNA, prepared by reverse transcription of a messenger RNA template, or a clone or amplified copy of such a molecule. Complementary DNA can be single-stranded or double-stranded.
  • Expression vector A DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription.
  • additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc.
  • Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.
  • the term "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator.
  • Gene A segment of chromosomal DNA that encodes a polypeptide chain.
  • a gene includes one or more regions encoding amino acids, which in some cases are interspersed with non-coding "intervening sequences" ("introns") , together with flanking, non-coding regions which provide for transcription of the coding sequence.
  • Molecules complementary to Polynucleotide molecules having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5* ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3' .
  • hematopoietic denotes the ability to stimulate the proliferation and/or differentiation of myeloid or lymphoid precursors as determined by standard assays. See, for example, Metcalf, Proc. Natl. Acad. Sci. USA 77: 5327-5330, 1980; Metcalf et al., J. Cell. Ph ⁇ siol. 116: 198-206, 1983; and Metcalf et al., Exp.
  • marrow cells are incubated in the presence of a test sample and a control sample. The cultures are then scored for cell proliferation and differentiation by visual examination and/or staining.
  • a particularly preferred assay is the MTT colorimetric assay of Mos an (J. Immunol. Meth. 65: 55-63, 1983; incorporated herein by reference) .
  • erythropoiesis denotes the proliferation and/or differentiation of erythroid precursor cells.
  • Standard measures of erythroid cell proliferation and differentiation include hematocrit and reticulocyte counts.
  • Hematocrit is a measurement of red blood cells, and is commonly expressed as the percentage of total blood volume which consists of erythrocytes.
  • Reticulocyte counts measure 1-2 day-old cells that contain mRNA (absent in mature erythrocytes) and aggregates of ribosomes as demonstrated by staining (Erslev, A., "Reticulocyte Enumeration", in Hematology, McGraw-Hill, NY, 1990) .
  • a reticulocyte count is the percentage of such cells per 500 or 1000 cells counted.
  • EPO is commercially available (R & D Systems, Minneapolis, MN and Amgen, Thousand Oaks, CA) and activity is measured by calibration against the second international reference preparation of erythropoietin (Annable et al., Bull. Wld. Hlth. Org. _VJ_ 99, 1972) using an in vivo assay which measures the incorporation of 56 Fe into red blood cells of exhypoxic polycythemic mice (Cotes et al., Nature 191:1065. 1961) or by in vi tro cell proliferation assay that uses a factor-dependent human erythroleukemic cell line, TF-1 (Kitamura et al., J. Cell.
  • the present invention is based in part upon the discovery that thrombopoietin (TPO) stimulates erythroid cell growth.
  • TPO thrombopoietin
  • sequences of cDNA clones encoding representative human and mouse TPO proteins are shown in SEQ ID N0:1 and SEQ ID NO:3, respectively and the corresponding amino acid sequence are shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.
  • sequences shown in SEQ ID NOS: 1 and 2 and the human genomic sequence shown in SEQ ID NOS:5 and 6, correspond to single alleles of the human gene, and that allelic variation is expected to exist. It will also be evident that one skilled in the art could engineer sites that would facilitate manipulation of the nucleotide sequence using alternative codons.
  • the present invention provides methods for stimulating erythropoiesis using proteins that are substantially homologous to the proteins of SEQ ID NO: 2 and their species homologs.
  • isolated is meant a protein which is found in a condition other than its native environment, such as apart from blood and animal tissue.
  • the isolated protein is substantially free of other proteins, particularly other proteins of animal origin. It is preferred to provide the proteins in a highly purified form, i.e. greater than 95% pure, more preferably greater than 99% pure.
  • substantially homologous is used herein to denote proteins having 50%, preferably 60%, more preferably at least 80%, sequence identity to the sequences shown in SEQ ID NO: 2 or their species homologs.
  • Such proteins will more preferably be at least 90% identical, and most preferably 95% or more identical to SEQ ID NO: 2 or their species homologs. Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-616, 1986 and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89_:10915-10919, 1992. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and Henikoff (ibid.) as shown in Table
  • Substantially homologous proteins are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 2) ; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification, such as a poly-histidine tract, an antigenic epitope or a binding domain. See, in general Ford et al.. Protein Expression and Purification 2.: 95- 107, 1991, which is incorporated herein by reference.
  • Aromatic phenylalanine tryptophan tyrosine
  • TPO and EPO may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244. 1081-1085, 1989) .
  • site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244. 1081-1085, 1989) .
  • single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (e.g. receptor binding, in vi tro or in vivo proliferative activity) to identify amino acid residues that are critical to the activity of the molecule.
  • Sites of ligand-receptor interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labeling. See, for example, de Vos et al., Science 255:306-312, 1992; Smith et al. , J. Mol. Biol. 224:899-904. 1992; Wlodaver et al., FEBS Lett. 309:59-64. 1992.
  • EPO Biologically active muteins of EPO based on elucidation of structure-function relationships have recently been identified (Boissel et al., J. of Biol. Chem. 268:15983-15993. 1993 and Higuchi et al. , J. Biol. Chem. 267:7703-7709. 1992).
  • EPO isoforms having different sialic acid compositions are disclosed by Strickland et al. EP 0428267.
  • cytokines are predicted to have a four-alpha helix structure, with the first and fourth helices being most important in ligand-receptor interactions and more highly conserved among members of the family.
  • TPO amino acid sequence shown in SEQ ID NO:2 alignment of cytokine sequences suggests that these helices are bounded by amino acid residues 29 and 53, 80 and 99, 108 and 130, and 144 and 168, respectively (boundaries are + 4 residues) . Helix boundaries of the mouse and other non-human TPOs can be determined by alignment with the human sequence. Other important structural aspects of TPO include the cysteine residues at positions 28, 50, 106 and 172 of SEQ ID NO:2.
  • the methods of the present invention include utilization of fragments of these proteins and isolated polynucleotide molecules encoding the fragments.
  • fragments of at least 10 amino acids in length that bind to an MPL receptor and polynucleotide molecules of at least 30 nucleotides in length encoding such polypeptides.
  • Polypeptides of this type are identified by known screening methods, such as by digesting the intact protein or synthesizing small, overlapping polypeptides or polynucleotides (and expressing the latter) , optionally in combination with the techniques of structural analysis disclosed above.
  • the resultant polypeptides are then tested for the ability to specifically bind the MPL receptor and stimulate cell proliferation via the MPL receptor. Binding is determined by conventional methods, such as that disclosed by Klotz, Science 217: 1247, 1982 ("Scatchard analysis"). Briefly, a radiolabeled test polypeptide is incubated with MPL receptor-bearing cells in the presence of increasing concentrations of unlabeled TPO. Cell-bound, labeled polypeptide is separated from free labeled polypeptide by centrifugation through phthalate oil. The binding affinity of the test polypeptide is determined by plotting the ratio of bound to free label on the ordinate versus bound label on the abscissa.
  • Binding specificity is determined by competition with cytokines other than TPO. Receptor binding can also be determined by precipitation of the test compound by immobilized MPL receptor (or the ligand-binding extracellular domain thereof) . Briefly, the receptor or portion thereof is immobilized on an insoluble support. The test compound is labeled, e.g. by metabolically labeling of the host cells in the case of a reco binant test compound, or by conventional, in vitro labeling methods (e.g. radio-iodination) . The labeled compound is then combined with the immobilized receptor, unbound material is removed, and bound, labeled compound is detected. Methods for detecting a variety of labels are known in the art.
  • Stimulation of proliferation is conveniently determined using the MTT colorimetric or 3 H- thymidine incorporation assay with MPL receptor-bearing cells.
  • Polypeptides are assayed for activity at various concentrations, typically over a range of 1 nm to 1 mM. Larger polypeptides of up to 50 or more residues, preferably 100 or more residues, more preferably about 140 or more residues, up to the size of the entire mature protein are also provided.
  • analysis and modeling of the amino acid sequence shown in SEQ ID NO:2 from residue 28 to residue 172, inclusive suggest that these portions of the molecules are cytokine-like domains capable of self assembly.
  • molecules containing this core cytokine-like domain plus one or more additional segments or domains of the primary translation product are also of interest.
  • the present invention provides hematopoietic polypeptides of at least 10 amino acid residues, preferably at least 50 residues, more preferably at least 100 residues and most preferably at least about 140 residues in length, wherein said polypeptides are substantially homologous to like-size polypeptides of SEQ ID NO:2.
  • the proteins used in the present invention for stimulating erythropoiesis can be produced in genetically engineered host cells according to conventional techniques.
  • Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells.
  • Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al.. Molecular Cloning: A Laboratory Manual. 2nd ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, and Ausubel et al., ibid., which are incorporated herein by reference. Production of reco binant EPO • has been described in Lin et al.
  • a DNA sequence encoding a cytokine is operably linked to a transcription promoter and terminator within an expression vector.
  • the vector will commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.
  • a secretory signal sequence also known as a leader sequence, prepro sequence or pre sequence
  • the secretory signal sequence is joined to the DNA sequence encoding a protein of interest in the correct reading frame.
  • Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the protein of interest, although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al. , U.S. Patent No. 5,143,830).
  • the secretory signal sequence may be that normally associated with a protein of interest, or may be from a gene encoding another secreted protein.
  • Yeast cells are a preferred host for producing cytokines for use within the present invention.
  • Methods for transforming yeast cells with exogenous DNA and producing recombinant proteins therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075, which are incorporated herein by reference.
  • Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g. leucine) .
  • a preferred vector system for use in yeast is the POT1 vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media.
  • a preferred secretory signal sequence for use in yeast is that of the S. cerevisiae MFctl gene (Brake, ibid.; Kurjan et al., U.S. Patent No. 4,546,082).
  • Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kings an et al., U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092, which are incorporated herein by reference) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454, which are incorporated herein by reference. Transformation systems for other yeasts, including Hansenula polymorpha , Schizosaccharomyces pombe, Kluyveromyces lactis,
  • Kluyveromyces fragilis, Ustilago maydis, Pichia pastoris, Pichia guillermondii and Candida mal tosa are known in the art. See, for example, Gleeson et al., J. Gen. Microbiol. JL3_2:3459-3465, 1986 and Cregg, U.S. Patent No. 4,882,279.
  • fungal cells are also suitable as host cells.
  • Aspergill us cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349, which is incorporated herein by reference.
  • Methods for transforming Acremoni um chrysogenum are disclosed by Sumino et al., U.S. Patent No. 5,162,228, which is incorporated herein by reference.
  • Methods for transforming Neurospora are disclosed by Lambowitz, U.S. Patent No. 4,486,533, which is incorporated herein by reference.
  • Cultured mammalian cells are also preferred hosts.
  • Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 2: 603 , 1981: Graham and Van der Eb, Virology 5_2.:456, 1973), electroporation (Neumann et al., EMBO J. 1:841-845, 1982) and DEAE-dextran mediated transfection (Ausubel et al., eds., Current Protocols in Molecular Biology. John Wiley and Sons, Inc., NY, 1987) , which are incorporated herein by reference.
  • cultured mammalian cells include the COS-l (ATCC No. CRL 1650) , COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC NO. CRL 10314), 293 (ATCC No.
  • CRL 1573 Graham et al., J. Gen. Virol. J3 :59-72, 1977
  • Chinese hamster ovary e.g. CHO-K1; ATCC No. CCL 61
  • Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland.
  • strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288.
  • Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978, which are incorporated herein by reference) and the adenovirus major late promoter.
  • Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as “transfectants”. Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as “stable transfectants.”
  • a preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin- type drug, such as G-418 or the like.
  • Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification.” Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes.
  • a preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate.
  • Other drug resistance genes e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase
  • hygromycin resistance multi-drug resistance
  • puromycin acetyltransferase can also be used.
  • eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian cells. Transformation of insect cells and production of foreign proteins therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222; Bang et al. , U.S. Patent No. 4,775,624; and WIPO publication WO 94/06463, which are incorporated herein by reference.
  • the use of Agrobacterium rhizogenes as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987.
  • Preferred prokaryotic host cells are strains of the bacteria Escherichia coli , although Bacill us and other genera are also useful. Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art (see, e.g., Sambrook et al., ibid.).
  • the protein When expressing the proteins in bacteria such as E. coli , the protein may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate.
  • the denatured protein is then refolded by diluting the denaturant.
  • the protein can be recovered from the periplasmic space in a soluble and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein.
  • Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells.
  • suitable media including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required.
  • the growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co- transfected into the host cell.
  • Transgenic animal technology may be employed to produce TPO and EPO for use in the present invention. It is preferred to produce the proteins within the mammary glands of a host female mammal. Expression in the mammary gland and subsequent secretion of the protein of interest into the milk overcomes many difficulties encountered in isolating proteins from other sources. Milk is readily collected, available in large quantities, and well characterized biochemically. Furthermore, the major milk proteins are present in milk at high concentrations (from about 1 to 15 g/1) .
  • mice and rats can be used (and are preferred at the proof-of-concept stage)
  • livestock mammals including, but not limited to, pigs, goats, sheep and cattle. Sheep are particularly preferred due to such factors as the previous history of transgenesis in this species, milk yield, cost and the ready availability of equipment for collecting sheep milk. See WIPO Publication WO 88/00239 for a comparison of factors influencing the choice of host species.
  • milk protein genes include those genes encoding caseins (see U.S. Patent No. 5,304,489, incorporated herein by reference) , beta-lactoglobulin, ⁇ -lactalbumin, and whey acidic protein.
  • the beta-lactoglobulin (BLG) promoter is preferred.
  • a region of at least the proximal 406 bp of 5' flanking sequence of the gene will generally be used, although larger portions of the 5' flanking sequence, up to about 5 kbp, are preferred, such as a -4.25 kbp DNA segment encompassing the 5• flanking promoter and non- coding portion of the beta-lactoglobulin gene. See Whitelaw et al., Bioche J. 286: 31-39, 1992. Similar fragments of promoter DNA from other species are also suitable.
  • beta-lactoglobulin gene may also be incorporated in constructs, as may genomic regions of the gene to be expressed. It is generally accepted in the art that constructs lacking introns, for example, express poorly in comparison with those that contain such DNA sequences (see Brinster et al., Proc. Natl. Acad. Sci. USA 85: 836-840, 1988; Palmiter et al., Proc. Natl. Acad. Sci. USA 88: 478-482, 1991; Whitelaw et al., Transgenic Res. 1: 3-13, 1991; WO 89/01343; WO 91/02318).
  • genomic sequences containing all or some of the native introns of a gene encoding the protein or polypeptide of interest thus the further inclusion of at least some introns from, e.g, the beta-lactoglobulin gene, is preferred.
  • One such region is a DNA segment which provides for intron splicing and RNA polyadenylation from the 3• non-coding region of the ovine beta-lactoglobulin gene. When substituted for the natural 3 1 non-coding sequences of a gene, this ovine beta-lactoglobulin segment can both enhance and stabilize expression levels of the protein or polypeptide of interest.
  • the region surrounding the initiation ATG of the cytokine sequence is replaced with corresponding sequences from a milk specific protein gene.
  • Such replacement provides a putative tissue-specific initiation environment to enhance expression. It is convenient to replace the entire cytokine pre-pro and 5' non-coding sequences with those of, for example, the BLG gene, although smaller regions may be replaced.
  • a DNA segment encoding the cytokine is operably linked to additional DNA segments required for its expression to produce expression units.
  • additional segments include the above-mentioned promoter, as well as sequences which provide for termination of transcription and polyadenylation of mRNA.
  • the expression units will further include a DNA segment encoding a secretory signal sequence operably linked to the segment encoding the cytokine.
  • the secretory signal sequence may be a native cytokine secretory signal sequence or may be that of another protein, such as a milk protein. See, for example, von Heinje, Nuc. Acids Res. 14: 4683-4690, 1986; and Meade et al., U.S. Patent No. 4,873,316, which are incorporated herein by reference.
  • Construction of expression units for use in transgenic animals is conveniently carried out by inserting a cytokine-encoding sequence into a plasmid or phage vector containing the additional DNA segments, although the expression unit may be constructed by essentially any sequence of ligations. It is particularly convenient to provide a vector containing a DNA segment encoding a milk protein and to replace the coding sequence for the milk protein with that of the cytokine of interest, thereby creating a gene fusion that includes the expression control sequences of the milk protein gene. In any event, cloning of the expression units in plasmids or other vectors facilitates the amplification of the cytokine sequence. Amplification is conveniently carried out in bacterial (e.g. E. coli ) host cells, thus the vectors will typically include an origin of replication and a selectable marker functional in bacterial host cells.
  • bacterial e.g. E. coli
  • the expression unit is then introduced into fertilized eggs (including early-stage embryos) of the chosen host species.
  • Introduction of heterologous DNA can be accomplished by one of several routes, including microinjection (e.g. U.S. Patent No. 4,873,191), retroviral infection (Jaenisch, Science 240: 1468-1474, 1988) or site-directed integration using embryonic stem (ES) cells (reviewed by Bradley et al.. Bio/Technology 10: 534-539, 1992).
  • the eggs are then implanted into the oviducts or uteri of pseudopregnant females and allowed to develop to term.
  • Offspring carrying the introduced DNA in their germ line can pass the DNA on to their progeny in the normal, Mendelian fashion, allowing the development of transgenic herds.
  • TPO and EPO are purified using methods generally known in the art, such as affinity purification and separations based on size, charge, solubility and other properties of the protein.
  • the medium is harvested and fractionated. Preferred methods of fractionation include affinity chromatography on concanavalin A or other lectin, thereby making use of the carbohydrate present on the protein.
  • TPO can also be purified using an immobilized MPL receptor protein or ligand-binding portion thereof or through the use of an affinity tag (e.g. polyhistidine, substance P or other polypeptide or protein for which an antibody or other specific binding agent is available) .
  • a specific cleavage site may be provided between the protein of interest and the affinity tag.
  • EPO has been purified from uremic patients exhibiting elevated EPO levels, see U.S. Patent Nos. 4,397,840, 4,303,650 and 3,865,801 and Miyake et al. J. Biol. Chem. 252:5558. 1977. EPO obtained from both uremic patients and recombinant methods have been purified using reverse-phase HPLC (Hewick et al. U.S. Patent No. 4,677,195)
  • TPO proteins can be used therapeutically wherever it is desirable to increase proliferation of hematopoietic cells in the bone marrow, such as in the treatment of cytopenia and anemia, such as that induced by aplastic anemia, myelodysplastic syndromes, autoimmune diseases, AIDS, chemotherapy or radiation.
  • compositions containing TPO will have useful application in the treatment of disorders characterized by low red blood cell production (anemia) , particularly when accompanied by low platelet production (thrombocytopenia) .
  • Various chemotherapeutic treatments of cancers and disease states are known to result in a combination of low platelet and erythrocyte levels in patients.
  • compositions of TPO have been found effective for increasing the level of circulating erythrocytes and erythrocyte precursor cells. Reduction in the circulating levels of these cells are known as anemia.
  • the erythrocyte level in blood is measured as the amount of hemoglobin per 100 ml or as the volume of packed red blood cells per 100 ml of blood. Patients are diagnosed as anemic if their hematocrit levels fall below 11-13 gm/100 ml of blood (depending upon the age and sex of the patient) .
  • the methods of the present invention are particularly useful for treatment of anemias associated with bone marrow failure, where a decrease in blood cell formation is associated with, for example, the toxic effects of chemotherapy.
  • TPO proteins have been found useful for simultaneous treatment of thrombocytopenia and anemia by increasing platelet production with a concurrent increase erythroid cell levels.
  • Anemia and thrombocytopenia are associated with a diverse group of diseases and clinical situations that may act alone or in concert to produce the condition.
  • Lowered platelet counts may be associated with anemia, for example, by dilutional losses due to massive transfusions, or abnormal destruction of bone marrow.
  • chemotherapeutic drugs used in cancer therapy may suppress development of platelet and erythroid progenitor cells in the bone marrow, and the resulting thrombocytopenia and anemia limit the chemotherapy and may necessitate transfusions.
  • certain malignancies can impair platelet and erythrocyte production and distribution.
  • Radiation therapy used to kill malignant cells also kills platelet and erythroid progenitor cells.
  • Abnormal destruction of platelets and erythrocytes can result from hematologic disorders such as leukemia and lymphoma or metastatic cancers involving bone marrow.
  • Other indications for the proteins of the present invention to treat concurrent anemia and thrombocytopenia include aplastic anemia and drug-induced marrow suppression resulting from, for example, chemotherapy or treatment of HIV infection with AZT.
  • Thrombocytopenia is manifested as increased bleeding, such as mucosal bleedings from the nasal-oral area or the gastrointestinal tract, as well as oozing from wounds, ulcers or injection sites.
  • Symptoms of anemia include dyspnea with exertion, dizziness, fatigue, and pallor of the skin and mucous membranes.
  • retinal hemorrhage can be present.
  • EPO has been used for stimulating erythrocyte production.
  • EPO is a an acidic glycoprotein of approximately 34,000 dalton molecular weight and may occur in three forms: ⁇ , ⁇ , and asialo.
  • the ⁇ and ⁇ forms differ slightly in carbohydrate components, but have the same potency, biological activity and molecular weight.
  • the asialo form is an ⁇ or ⁇ form with the terminal carbohydrate (sialic acid) removed.
  • Erythropoietin is present in very low concentrations in plasma when the body is in a healthy state and tissues are receiving sufficient oxygenation from the existing number of erythrocytes. See, for example, Lin et al., U.S. Patent 4,703,008; Lin et al., WO 85/02610; Fritsch et al. EP 0411678; Hewick et al., EP 0209539 and Hewick et al., U.S.
  • the present invention does not always require the administration of exogenous EPO.
  • a reduction in the level of red blood cells will in some cases result in an elevation in the endogenous levels of EPO (greater than 500 mU/ml of plasma) and administration of TPO alone may be sufficient.
  • erythropoietin is advantageoulsy administered with compositions of TPO.
  • EPO is administered to uremic patients where the hemoglobin concentration is less than 10 gm/100 ml of blood.
  • the route of administration can be either intravenous (IV) or subcutaneous (SC) and frequency varies from daily to weekly depending upon patient's physical condition (De Marchi et al. Clin. and Experim. Rheumatol. 11:429-444, 1993; Miller et al., N. Eng. J. of Med. 322:1689-1692. 1990; Nissenson et al., Annals of Int. Med. 114:402-416- 1991; Erslev, Sem. Oncol. 19 (8) Suppl. 8.:14-18, 1992 and PROCIT Epotin-alfa package insert, Amgen, Thousand Oaks, CA) .
  • TPO and EPO are formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods.
  • Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours.
  • pharmaceutical formulations will include the hematopoietic proteins in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like.
  • Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc.
  • TPO and EPO may be combined with other cytokines, particularly early-acting cytokines such as stem cell factor, IL-3, IL-6, IL-11 or GM-CSF.
  • the cytokines may be combined in a single formulation or may be administered in separate formulations. Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences. Gennaro, ed. , Mack Publishing Co., Easton PA, 1990, which is incorporated herein by reference.
  • Therapeutic doses of TPO will generally be in the range of 1 x 10 5 to 100 x 10 5 units/kg of patient weight per day, preferably 5 x 10 5 to 50 x 10 5 units/kg per day.
  • Therapeutic doses of EPO will generally be in the range of 10-150 U/kg of patient weight per day, preferably 50-150 U/kg per day.
  • the exact dose will be determined by the clinician according to accepted standards, taking into account the nature and severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art.
  • the proteins will commonly be administered over a period of up to 28 days following chemotherapy, radiation therapy or bone-marrow transplant or until a platelet count of >20,000/mm 3 , preferably >50,000/mm 3 , a hematocrit of 30-33% and reticulocyte counts that are at least 2-fold over baseline are achieved.
  • TPO or EPO is an amount sufficient to produce a clinically significant increase in the proliferation and/or differentiation of lymphoid or myeloid progenitor cells, which will be manifested as an increase in circulating levels of mature cells (e.g. platelets or erythrocytes) .
  • Treatment of platelet disorders will thus be continued until a platelet count of at least 20,000/mm 3 , preferably 50,000/mm 3 , is reached.
  • TPO and EPO can also be administered in combination with other cytokines such as IL-3, -6 and -11; stem cell factor; G-CSF and GM-CSF.
  • cytokines such as IL-3, -6 and -11; stem cell factor; G-CSF and GM-CSF.
  • daily doses of other cytokines will in general be: GM-CSF, 5-15 .g/kg; IL-3, 1-5 g/kg; and G- CSF, 1-25 ⁇ g/kg.
  • TPO and EPO can also be used ex vi vo, such as in autologous marrow culture. Briefly, bone marrow is removed from a patient prior to chemotherapy and treated with TPO, optionally in combination with EPO, optionally in combination with one or more additional cytokines. The treated marrow is then returned to the patient after chemotherapy to speed the recovery of the marrow.
  • TPO alone and in combination with EPO, can also be used for the ex vivo expansion of marrow or peripheral blood progenitor (PBPC) cells.
  • PBPC peripheral blood progenitor
  • marrow Prior to chemotherapy treatment, marrow can be stimulated with stem cell factor (SCF) or G-CSF to release early progenitor cells into peripheral circulation.
  • SCF stem cell factor
  • G-CSF G-CSF
  • TPO and EPO optionally in combination with one or more other cytokines, including but not limited to SCF, G-CSF, IL-3, GM-CSF, IL-6 or IL- 11, to differentiate and proliferate into high-density megakaryocyte cultures, which can then be returned to the patient following high-dose chemotherapy.
  • cytokines including but not limited to SCF, G-CSF, IL-3, GM-CSF, IL-6 or IL- 11, to differentiate and proliferate into high-density megakaryocyte cultures, which can then be returned to the patient following high-dose chemotherapy.
  • the invention is further illustrated by the following non-limiting examples.
  • CFU-E erythroid colony forming units
  • Bone marrow cells were isolated from BDFi mice
  • Units of TPO activity were determined using the following assay.
  • An asymptotic mitogenic activity curve was generated using this standard solution (conditioned culture medium) and BaF3/MPLRl.l cells (IL-3-dependent cells expressing a stably transfected Type I mouse MPL receptor) .
  • the point of 1/2 maximal activity (average of 16 curves) was assigned the value of 50 U/ml.
  • the original standard solution was calculated to contain 26,600 U/ml mouse TPO.
  • each well of each plate were transferred to a filter/plate using a Packard apparatus.
  • the filters were washed 8 times with water, and the filters were dried and counted. Units of TPO activity in each sample well were determined by comparison to the standard curve.
  • Human EPO (Amgen Inc., Thousand Oaks, CA) was added at varying concentrations in the range from 0 to 300 mUnits/ml with or without 120 units TPO. Clotting was initiated by the addition of 10% citrated bovine plasma.
  • the bone marrow cultures were incubated for two days at 37 ⁇ C in a fully humidified atmosphere containing 5% C0 2 . Erythroid colonies contained greater than 40 cells. After incubation, the clots were harvested, dried, stained with benzidine and erythroid colonies were counted (Broudy et al. Arch, of Bioche . and Biophys. 265:329-336, 1988). The results have been indexed to that of the maximal colony growth and represent the mean of at least three separate experiments of two to three replicate plates.
  • Figure 1 shows that at physiological concentrations of EPO, in the range of 0-100 mUnits/ml, the addition of 120 U/ml TPO results in a significant increase the number of erythroid progenitor cell colonies.
  • TPO-treated animals have elevated reticulocyte counts when compared to untreated animals.
  • mice Ten male BALB/c mice (Simonsen Labs, Gilroy, CA; approximately 8 weeks old) were divided into a TPO-treated group of five animals and a sham group of five animals.
  • a 12.5 kU dose of mouse recombinant TPO was prepared in 20 mM Tris (pH 8.1), 0.9% NaCl and 0.25% rabbit serum albumin (RSA) .
  • the sham animals were treated with buffer alone.
  • CBC complete blood counts
  • the animals were bled and sacrificed, and CBCs and reticulocyte counts were measured.
  • TPO administered to animals that had been treated with radiation and a chemotherapeutic drug showed increased erythropoietic recovery when compared to untreated animals.
  • Group 1 8 mice treated with 500 cGy radiation + 1.2 mg carboplatin + TPO buffer
  • Group 2 8 mice treated with 500 cGy radiation + 1.2 mg carboplatin + 25 kU TPO/day for 14 days
  • Group 3 8 mice treated with 500 cGY radiation +
  • TPO was prepared in a buffer containing 20 mM Tris (pH 8.1), 0.9% NaCl and 0.25% RSA.
  • the mice were bled and CBCs were measured on days 0 (to establish baseline) , 4, 6, 8, 10, 11 (CBC and reticulocyte counts), 13 (CBC and reticulocyte counts), 15, 18, 20, 22 and 25 (CBC and reticulocyte counts) and then sacrificed.
  • TPO-treated animals had a statistically shorter period of red blood cell nadir and their red blood cell levels recovered to baseline significantly faster than animals treated with buffer only.
  • AAC GAG CTC CCA AAC AGG ACT TCT GGA TTG TTG GAG ACA AAC TTC ACT 624 Asn Glu Leu Pro Asn Arg Thr Ser Gly Leu Leu Glu Thr Asn Phe Thr 195 200 205
  • AAG ATT CAG GGG AGA GGC CCC ATA CAG GGA GCC ACT TCA GTT
  • MOLECULE TYPE DNA (genomic)
  • AAAAGACTGA ATCAAGATTC AAATCACTGA AAGACTAGGT CAAAAACAAG GTGAAACAAC 1786
  • CTCTCTTCCA TCTCTTTCTC AG GAG GAG ACC AAG GCA CAG GAC ATT CTG GGA 3338

Abstract

L'invention décrit des procédés de stimulation de l'érythropoïèse à l'aide de protéines hématopoïétiques, qui peuvent servir à stimuler l'érythropoïèse dans la moelle osseuse et les érythrocytes périphériques in vitro et in vivo. L'invention décrit en outre des procédés pour le traitement de la thrombocytopénie et de l'anémie chez les patients.
PCT/US1995/001829 1994-02-14 1995-02-09 Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques WO1995021626A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP95910252A EP0723456A1 (fr) 1994-02-14 1995-02-09 Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques
NZ281482A NZ281482A (en) 1994-02-14 1995-02-09 The stimulation of erythropoiesis using thrombopoietin and erythropoietin
CA002169173A CA2169173C (fr) 1994-02-14 1995-02-09 Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques
AU18435/95A AU1843595A (en) 1994-02-14 1995-02-09 Methods for stimulating erythropoiesis using thrombopoietin
FI960930A FI960930A0 (fi) 1994-02-14 1996-02-28 Menetelmiä erytropoieesin stimuloimiseksi trombopoietiinia käyttämällä

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US19602594A 1994-02-14 1994-02-14
US08/196,025 1994-02-14
US20319794A 1994-02-25 1994-02-25
US08/203,197 1994-02-25
US21520394A 1994-03-21 1994-03-21
US08/215,203 1994-03-21
US25249194A 1994-06-01 1994-06-01
US08/252,491 1994-06-01
US28841794A 1994-08-09 1994-08-09
US08/288,417 1994-08-09
US33556694A 1994-11-07 1994-11-07
US08/335,566 1994-11-07
US34774894A 1994-12-01 1994-12-01
US08/347,748 1994-12-01

Publications (1)

Publication Number Publication Date
WO1995021626A1 true WO1995021626A1 (fr) 1995-08-17

Family

ID=27569260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/001829 WO1995021626A1 (fr) 1994-02-14 1995-02-09 Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques

Country Status (6)

Country Link
EP (1) EP0723456A1 (fr)
AU (1) AU1843595A (fr)
CA (1) CA2169173C (fr)
FI (1) FI960930A0 (fr)
NZ (1) NZ281482A (fr)
WO (1) WO1995021626A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015758A2 (fr) * 1994-11-07 1996-05-30 University Of Washington Procedes de stimulation de l'erythropoiese a l'aide de la trombopoietine
WO1996028182A1 (fr) * 1995-03-15 1996-09-19 Kirin Brewery Company, Limited Procede pour empecher l'adsorption de tpo et composition stable contenant du tpo
WO1996028181A1 (fr) * 1995-03-15 1996-09-19 Kirin Brewery Company, Limited Procede pour empecher l'adsorption de tpo et composition contenant de la tpo
WO1996029411A1 (fr) * 1995-03-17 1996-09-26 Transkaryotic Therapies, Inc. Production et administration d'une proteine
WO1996041642A1 (fr) * 1995-06-08 1996-12-27 Kirin Brewery Company, Limited Composition lyophilisee stable contenant de la thrombopoietine (tpo)
WO1997016535A3 (fr) * 1995-10-30 1997-08-28 Sandoz Ltd PROCEDES D'UTILISATION DE LIGANDS Mpl AVEC DES CELLULES SOUCHES HUMAINES PRIMITIVES
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
WO2002015926A1 (fr) * 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes
US6465430B1 (en) 1995-06-07 2002-10-15 Smithkline Beecham Corporation Peptides and compounds that bind to a thrombopoietin receptor
US6565844B1 (en) 1991-11-05 2003-05-20 Transkaryotic Therapies, Inc. Protein production and protein delivery
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
WO2007087241A2 (fr) * 2006-01-23 2007-08-02 Mcw Research Foundation, Inc. Procédé de protection contre une maladie ischémique
WO2007094781A1 (fr) * 2006-02-14 2007-08-23 Janssen Pharmaceutica N.V. Utilisation de composés peptidiques tpo et des compositions pharmaceutiques correspondantes dans le traitement de l'anémie
US7576056B2 (en) 2003-08-28 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US8067367B2 (en) 2002-09-18 2011-11-29 Janssen Pharmaceutica, N.V. Methods of increasing platelet and hematopoietic stem cell production

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE FILE SERVER STN KARLSRUHE; TAKAHASHI ET AL *
EVATT ET AL: "RELATIONSHIPS BETWEEN THROMBOPOIESIS AND ERYTHROPOIESIS:WITH STUDIES OF THE EFFECTS OF PREPARATIONS OF THROMBOPOIETIN AND ERYTHROPOIETIN", BLOOD, vol. 48, no. 4, pages 547 - 558, XP002001520 *
MCDONALD: "THROMBOPOIETIN.ITS BIOLOGY,CLINICAL ASPECTS,AND POSSIBILITIES", THE AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY, vol. 14, no. 1, pages 8 - 21, XP002001521 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6565844B1 (en) 1991-11-05 2003-05-20 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
WO1996015758A3 (fr) * 1994-11-07 1996-07-11 Univ Washington Procedes de stimulation de l'erythropoiese a l'aide de la trombopoietine
WO1996015758A2 (fr) * 1994-11-07 1996-05-30 University Of Washington Procedes de stimulation de l'erythropoiese a l'aide de la trombopoietine
WO1996028182A1 (fr) * 1995-03-15 1996-09-19 Kirin Brewery Company, Limited Procede pour empecher l'adsorption de tpo et composition stable contenant du tpo
WO1996028181A1 (fr) * 1995-03-15 1996-09-19 Kirin Brewery Company, Limited Procede pour empecher l'adsorption de tpo et composition contenant de la tpo
WO1996029411A1 (fr) * 1995-03-17 1996-09-26 Transkaryotic Therapies, Inc. Production et administration d'une proteine
US6506362B1 (en) 1995-06-07 2003-01-14 Glaxo Group Limited Labeled compounds that bind to a thrombopoietin receptor
US6465430B1 (en) 1995-06-07 2002-10-15 Smithkline Beecham Corporation Peptides and compounds that bind to a thrombopoietin receptor
US6121238A (en) * 1995-06-07 2000-09-19 Glaxo Wellcome Inc. Peptides and compounds that bind to a receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
WO1996041642A1 (fr) * 1995-06-08 1996-12-27 Kirin Brewery Company, Limited Composition lyophilisee stable contenant de la thrombopoietine (tpo)
WO1997016535A3 (fr) * 1995-10-30 1997-08-28 Sandoz Ltd PROCEDES D'UTILISATION DE LIGANDS Mpl AVEC DES CELLULES SOUCHES HUMAINES PRIMITIVES
US7416887B2 (en) 1995-10-30 2008-08-26 Novartis Ag Methods for use of MPL ligands with primitive human stem cells
US6326205B1 (en) 1995-10-30 2001-12-04 Systemix, Inc. Methods for use of Mpl ligands with primitive human stem cells
AU717783B2 (en) * 1995-10-30 2000-03-30 Novartis Ag Methods for use of Mpl ligands with primitive human stem cells
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US6916470B2 (en) 1995-10-30 2005-07-12 Novartis Ag Methods for use of mpl ligands with primitive human stem cells
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US8227422B2 (en) 1996-06-07 2012-07-24 Glaxosmithkline Llc Peptides and compounds that bind to a receptor
WO2002015926A1 (fr) * 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes
US8283313B2 (en) 2002-09-18 2012-10-09 Janssen Pharmaceutica, Nv Methods of increasing platelet and hematopoietic stem cell production
US8067367B2 (en) 2002-09-18 2011-11-29 Janssen Pharmaceutica, N.V. Methods of increasing platelet and hematopoietic stem cell production
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7576056B2 (en) 2003-08-28 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
WO2007087241A3 (fr) * 2006-01-23 2007-09-13 Mcw Res Found Inc Procédé de protection contre une maladie ischémique
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
WO2007087241A2 (fr) * 2006-01-23 2007-08-02 Mcw Research Foundation, Inc. Procédé de protection contre une maladie ischémique
US8518883B2 (en) 2006-01-23 2013-08-27 Mcw Research Foundation, Inc. Method of reducing deleterious effects of ischemia by administration of a thrombopoietin receptor ligand
EA015562B1 (ru) * 2006-02-14 2011-08-30 Янссен Фармацевтика Н.В. Применение пептидных соединений тро и фармацевтических композиций для лечения анемии
JP2009526841A (ja) * 2006-02-14 2009-07-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｐｏペプチド化合物及び薬学的組成物の貧血症の処置における使用
WO2007094781A1 (fr) * 2006-02-14 2007-08-23 Janssen Pharmaceutica N.V. Utilisation de composés peptidiques tpo et des compositions pharmaceutiques correspondantes dans le traitement de l'anémie
AU2006338308B2 (en) * 2006-02-14 2012-11-01 Janssen Pharmaceutica N.V. Use of TPO peptide compounds and pharmaceutical compositions in the treatment of anemia
CN101374540B (zh) * 2006-02-14 2013-03-06 詹森药业有限公司 Tpo肽化合物和药物组合物在治疗贫血中的用途
NO341872B1 (no) * 2006-02-14 2018-02-12 Janssen Pharmaceutica Nv Anvendelse av TPO-peptidforbindelser og farmasøytiske sammensetninger i behandling av anemi

Also Published As

Publication number Publication date
AU1843595A (en) 1995-08-29
CA2169173A1 (fr) 1995-08-17
FI960930A (fi) 1996-02-28
CA2169173C (fr) 2002-10-15
EP0723456A1 (fr) 1996-07-31
NZ281482A (en) 2000-09-29
FI960930A0 (fi) 1996-02-28

Similar Documents

Publication Publication Date Title
US5989537A (en) Methods for stimulating granulocyte/macrophage lineage using thrombopoietin
EP0723456A1 (fr) Procede de stimulation de l'erythropoiese a l'aide de proteines hematopoietiques
Hirayama et al. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors
Carver-Moore et al. Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice
Borge et al. Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro
AU689373B2 (en) Method for secreting thrombopoietin polypeptides
EP0892849B1 (fr) Procedes d'utilisation du gene obese et de son produit genique afin de stimuler le developpement des cellules hematopo etiques
Tong et al. In vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells
US6316254B1 (en) Methods for stimulating erythropoiesis using hematopoietic proteins
EP0639979B1 (fr) LIGAND POUR LE RECEPTEUR DE c-$i(KIT) ET PROCEDES D'UTILISATION
AU693032B2 (en) Methods for increasing hematopoietic cells
US6099830A (en) Methods for stimulating erythropoiesis using hematopoietic proteins
WO1996017062A1 (fr) Thrombopoietine de faible poids moleculaire
EP0804480A1 (fr) Thrombopoietine purifiee et son procede d'obtention
CA2433933A1 (fr) Utilisation de lp82 pour traiter les troubles hematopoietiques
AU725159B2 (en) Methods for stimulating erythropoiesis using thrombopoietin
AU723793B2 (en) Hematopoietic protein and materials and methods for making it
MXPA97009244A (en) Methods to increase hematopoyeti cells
Tong et al. In vivo administration of recombinant methionyl human stem cell
AU5966796A (en) Therapy using lymphotoxin and thrombopoietin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995910252

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 281482

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2169173

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 960930

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1995910252

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995910252

Country of ref document: EP